Who are the leading companies in the Low-grade glioma Market Landscape?
What is the Low-grade glioma?
Low-grade glioma (LGG’s) are a diverse group of primary brain tumors that often arise in young, otherwise healthy patients and generally have an indolent course with longer-term survival in comparison with high-grade glioma. Moreover, in this type of brain tumor with a relatively good prognosis and prolonged survival, the potential benefits of treatment must be carefully weighed against potential treatment-related risks. Low-grade astrocytic tumors include diffuse astrocytoma, pilomyxoid astrocytoma, and pleomorphic xanthoastrocytoma (WHO grade II), as well as subependymal giant cell astrocytoma (SEGA) and pilocytic astrocytoma (WHO grade I tumors). IDH1 and IDH2 are the most commonly mutated genes in low grade glioma, with mutations estimated to occur in > 70% of cases. BRAF V600E point mutations are occasionally observed in pilocytic astrocytoma; the mutations are also observed in nonpilocytic pediatric low-grade glioma, including ganglioglioma, desmoplastic infantile ganglioglioma, and approximately two-thirds of pleomorphic xanthoastrocytomas.
What is the Low-grade Glioma Market?
DelveInsight’s “Low-grade Glioma Market Insights, Epidemiology and Market Forecast– 2032” report delivers an in-depth understanding of the Low-grade glioma, historical and forecasted epidemiology as well as the Low-grade glioma market trends in the United States, EU-5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
What is the Low-grade glioma Market Size in 7MM?
The total Low-grade glioma market size was accounted for USD 969 Million in the year 2021 and is estimated to grow during the study period (2019–2032).
Who are the leading Low-grade glioma Market Companies?
The key players in the Low-grade glioma market who are in different phases of developing Low-grade glioma Therapies are — Day One Biopharmaceuticals, AnHeart Therapeutics, Beigene, SpringWorks Therapeutics, Servier, Helsinn, Forma Therapeutics, Hoffmann-La Roche, Incyte, Eli Lilly, and others.
What is the Low-grade Glioma Market Report?
Low-grade glioma market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Low-grade glioma market size from 2019 to 2032. The report also covers current Low-grade glioma treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
What is the Low-grade glioma Marketed Drug?
· Trametinib + Dabrafenib: Novartis Pharmaceuticals
Novartis Pharmaceuticals is developing trametinib + dabrafenib which is an oral small-molecule inhibitor Inhibits MAPK pathway and inhibits cell growth of various BRAFV600E positive tumors. Currently, the company is conducting Phase II trials on children and adolescent patients with BRAF V600 mutation-positive relapsed or refractory HGG or BRAFV600 mutation-positive Low-grade glioma. Recently in June 2022, Novartis announced that the US FDA has granted accelerated approval to Tafinlar (dabrafenib) + Mekinist (trametinib) for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options.
What are the Low-grade glioma Emerging Drugs?
· DAY101: Day One Biopharmaceuticals
· Vorasidenib: Servier
· AB-218: AnHeart Therapeutics
· Mirdametinib: SpringWorks Therapeutics
What is the Low-grade glioma Market Outlook?
At present, the therapeutic landscape of Low-grade glioma is devoid of approved treatment, and there is a substantial unmet need for a therapy to slow its worsening. The pathophysiology of Low-grade glioma is poorly understood. The low-grade glioma segment is anticipated to be a highly lucrative segment in the near future due to more treatment options available and early detection of tumor of this grade. Low-grade gliomas progress into HGGs over a period, so there is an urgent need for upcoming therapies to stop the progression of Low-grade glioma into HGG, especially in the Grade 2 stage.
There is more focus on high-grade glioma than low-grade glioma as patients with low-grade glioma typically lives longer than those with high-grade glioma. Traditional outcome measures in clinical cancer research have been confined to overall survival, progression-free survival, and radiological response to treatment. Palliation and the maintenance or improvement of quality of life are also important, and this recognition has resulted in that health-related quality of life.
Many pharmaceutical companies are working to develop a novel approach to treat this condition. Key players like Day One Biopharmaceuticals (DAY101), AnHeart Therapeutic (AB-218), SpringWorks Therapeutics (mirdametinib), Servier (vorasidenib [AG- 881]), and others are focusing on indications like Low-grade glioma to fulfill the gap of this high unmet need.
Contact Us
Yash Bhardwaj
info@delveinsight.com
